Point of Care Molecular Diagnostics Market - Global Forecast to 2030
商品番号 : SMB-11195
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年9月 |
| ページ数 | 328 |
| 図表数 | 404 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、ポイントオブケア分子診断市場を、製品・サービス（アッセイ＆キット、機器・分析装置、ソフトウェア・サービス）、技術（RT-PCR、INAAT、その他）、サンプルの種類（血液サンプル、尿、その他）、用途（呼吸器疾患、性感染症、院内感染、がん、肝炎、胃腸疾患、その他）、エンドユーザー（診療所・クリニック、病院、研究機関、その他）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）別に分類しています。本レポートでは、ポイントオブケア分子診断市場の成長に影響を与える主要要因（成長促進要因、阻害要因、機会、課題など）に関する詳細な情報を提供しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、主要戦略、買収、契約に関する洞察を提供しています。本レポートでは、ポイントオブケア分子診断市場に関連する新製品の発売や最近の動向についても取り上げています。さらに、ポイントオブケア分子診断市場エコシステムにおける新興企業の競合分析も含まれています。
本レポートは、POC分子診断市場全体とそのサブセグメントの収益について、ほぼ正確な推定値を提供することで、市場リーダー企業と新規参入企業を支援します。ステークホルダーの皆様は、本レポートを通じて競争環境を理解し、事業のポジショニングを改善し、効果的な市場開拓戦略を策定するための洞察を得ることができます。さらに、本レポートは、主要な推進要因、制約要因、機会、課題など、市場動向に関する理解も提供します。
世界のポイントオブケア（POC）分子診断市場は、2025年の43億米ドルから2030年には70億9000万米ドルに達し、年平均成長率（CAGR）10.5%で成長すると予測されています。この市場を牽引しているのは、様々な医療現場でより迅速な臨床判断を可能にする分散型検査への注目度の高まりです。これは、タイムリーな意思決定が不可欠な、リソースが限られている地域や遠隔地では特に重要です。研究開発投資の増加は、信頼性を維持しながら分子検査を容易にする、高度でポータブルな技術の開発をさらに後押ししています。これらのイノベーションは、医療提供者が従来の検査室以外の場所でPOCソリューションを導入する上で役立っています。
The global point-of-care molecular diagnostics market is projected to reach USD 7.09 billion by 2030, from USD 4.30 billion in 2025, with a CAGR of 10.5%. The market is primarily driven by the increasing focus on decentralized testing, which facilitates faster clinical decisions across various care settings. This is especially crucial in resource-limited or remote areas where timely decision-making is vital. Rising R&D investments are further supporting the development of advanced, portable technologies that make molecular testing easier while maintaining reliability. These innovations are helping healthcare providers adopt point-of-care solutions outside traditional laboratory settings.
Assays & kits accounted for the highest growth rate in the point-of-care molecular diagnostics market by product & service.
The point-of-care molecular diagnostics market is classified into assays & kits, instruments & analyzers, and software & services. Assays & kits are expected to be the fastest-growing segment during the forecast period. This growth is fueled by the rising need for quick and precise testing solutions that can be used directly at the point of care. The frequent use and ongoing demand for assay kits across various clinical settings, as well as their growing role in diagnosing diverse conditions, are key factors supporting this trend. As healthcare systems continue to prioritize early detection and decentralized testing, the demand for reliable and easy-to-use molecular assay kits is likely to increase steadily.
Blood is the fastest-growing segment in the point-of-care molecular diagnostics market by sample type.
The point-of-care molecular diagnostics market includes various sample types, such as blood, urine, and others. The blood sample is expected to experience the highest CAGR during the forecast period, driven by its broad use across different diseases and the availability of minimally invasive collection methods. Blood-based molecular tests provide high sensitivity and specificity, making them suitable for detecting a wide range of infectious diseases, including HIV, hepatitis, and sepsis. The increasing demand for rapid diagnostics in critical care settings, where blood is often the preferred sample, further supports this growth. Additionally, technological advancements have improved the efficiency and reliability of blood-based point-of-care testing, promoting its wider adoption.
Asia Pacific exhibits the fastest growth in the point-of-care molecular diagnostics market.
The global market for point-of-care molecular diagnostics is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience the fastest growth in this market. This expansion is fueled by increasing healthcare spending, broader access to diagnostic services, and more government efforts to improve early disease detection. Additionally, ongoing investments in healthcare infrastructure and rising awareness of the benefits of point-of-care testing create positive conditions for market growth. The presence of emerging economies like China and India further boosts growth prospects due to their growing focus on enhancing diagnostic capabilities.
The break-up of the profile of primary participants in the point-of-care molecular diagnostics market:
- By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
- By Designation: C-level – 27%, D-level – 18%, and Others – 55%
- By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa – 4%
The key players in this market are Danaher Corporation (US), bioMérieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), QuidelOrtho Corporation (US), Co-Diagnostics, Inc. (US), Biocartis Group NV (Belgium), SD Biosensor, INC. (South Korea), genedrive plc (UK), Binx Health, Inc. (US), Molbio Diagnostics Pvt. Ltd. (India), Genomadix (Canada), Visby Medical, Inc. (US), QuantuMDx Group Ltd. (UK), DetectaChem (US), Labsystems Diagnostics Oy (Finland), Akonni Biosystems, Inc. (US), Ubiquitome Limited (New Zealand), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), OpGen, Inc. (US), Nuclein, LLC (US), Genes2Me (India), Axxin (Australia), and Huwel Lifesciences (India).
Research Coverage:
This report categorizes the point-of-care molecular diagnostics market by product & service (assay & kits, instruments & analyzers, and software & services), technology (RT-PCR, INAAT, other technologies), sample type (blood samples, urine, and other sample types), application (respiratory diseases, sexually transmitted diseases, hospital-acquired infections, cancer, hepatitis, gastrointestinal disorders, and other applications), end user (physicians’ offices/clinics, hospitals, research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report includes detailed information about the major factors affecting the growth of the point-of-care molecular diagnostics market, such as drivers, restraints, opportunities, and challenges. A thorough analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. The report also covers new product launches and recent developments related to the point-of-care molecular diagnostics market. Additionally, it includes a competitive analysis of upcoming startups within the point-of-care molecular diagnostics market ecosystem.
Reasons to buy this report:
The report will assist market leaders and new entrants by providing near-accurate estimates of the revenue for the overall point-of-care molecular diagnostics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. Additionally, the report offers stakeholders an understanding of market dynamics, including key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising incidence of infectious diseases and cancer, increasing focus on decentralized diagnostics, improved awareness of early detection of infectious diseases), opportunities (untapped growth potential across emerging economies), restraints (unfavorable reimbursement scenario, substantial initial investment and low cost-benefit ratio), and challenges (stringent and time-consuming regulatory policies, emergence of alternative technologies) influencing the growth of the point-of-care molecular diagnostics market
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the point-of-care molecular diagnostics market
- Market Development: Comprehensive information about lucrative markets – the report analyses the point-of-care molecular diagnostics market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point-of-care molecular diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher Corporation (US), bioMérieux (France), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), and QIAGEN N.V. (Netherlands)
Table of Contents
1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 STUDY SCOPE 33
1.3.1 MARKETS COVERED & REGIONAL SCOPE 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 35
1.3.4 CURRENCY CONSIDERED 35
1.4 KEY STAKEHOLDERS 35
1.5 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH DATA 37
2.2 RESEARCH APPROACH 37
2.2.1 SECONDARY DATA 38
2.2.1.1 Key secondary sources 38
2.2.1.2 Key data from secondary sources 39
2.2.2 PRIMARY DATA 40
2.2.2.1 Primary sources 40
2.2.2.2 Key data from primary sources 41
2.2.2.3 Key industry insights 42
2.2.2.4 Breakdown of primary interviews 42
2.3 MARKET SIZE ESTIMATION 43
2.3.1 BOTTOM-UP APPROACH 44
2.3.1.1 Approach 1: Company revenue estimation approach 44
2.3.1.2 Approach 2: Presentations of companies and primary interviews 44
2.3.1.3 Growth forecast 45
2.3.1.4 CAGR projections 45
2.3.2 TOP-DOWN APPROACH 46
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 47
2.5 MARKET SHARE ASSESSMENT 48
2.6 RESEARCH ASSUMPTIONS 49
2.6.1 PARAMETRIC ASSUMPTIONS 49
2.7 RESEARCH LIMITATIONS 49
2.8 RISK ASSESSMENT 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHTS 56
4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW 56
4.2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT &
SERVICE, 2025 VS. 2030 (USD MILLION) 57
4.3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 57
4.4 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2025 VS. 2030 (USD MILLION) 58
4.5 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 58
4.6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 59
4.7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing prevalence of infectious diseases and cancer 61
5.2.1.2 Increasing focus on decentralized diagnostics and subsequent rise in R&D funding 62
5.2.1.3 Growing awareness associated with early disease diagnosis 63
5.2.1.4 Increasing use of POC diagnostic tests 64
5.2.2 RESTRAINTS 64
5.2.2.1 Unfavorable reimbursements 64
5.2.2.2 High capital investments and low cost-benefit ratio 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 Growth opportunities in emerging economies 65
5.2.4 CHALLENGES 66
5.2.4.1 Stringent regulatory guidelines that impact product commercialization 66
5.2.4.2 Introduction of alternative technologies 67
5.3 PRICING ANALYSIS 67
5.3.1 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023−2025 67
5.3.2 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023−2025 68
5.3.3 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025 68
5.4 PATENT ANALYSIS 70
5.4.1 LIST OF KEY PATENTS 71
5.5 VALUE CHAIN ANALYSIS 72
5.6 SUPPLY CHAIN ANALYSIS 73
5.7 TRADE ANALYSIS 74
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 74
5.7.2 IMPORT DATA (HS CODE 3822) 75
5.7.3 EXPORT DATA (HS CODE 3822) 75
5.8 ECOSYSTEM ANALYSIS 76
5.8.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 76
5.9 PORTER’S FIVE FORCES ANALYSIS 77
5.9.1 THREAT OF NEW ENTRANTS 78
5.9.2 BARGAINING POWER OF SUPPLIERS 78
5.9.3 THREAT OF SUBSTITUTES 78
5.9.4 BARGAINING POWER OF BUYERS 78
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 79
5.10 REGULATORY LANDSCAPE 79
5.10.1 REGULATORY FRAMEWORK 79
5.10.1.1 North America 79
5.10.1.1.1 US 79
5.10.1.1.2 Canada 79
5.10.1.2 EUROPE 79
5.10.1.2.1 Germany 80
5.10.1.2.2 UK 80
5.10.1.2.3 France 81
5.10.1.2.4 Italy 81
5.10.1.3 Asia Pacific 81
5.10.1.3.1 China 81
5.10.1.3.2 Japan 81
5.10.1.3.3 India 82
5.10.1.4 Latin America 82
5.10.1.4.1 Brazil 82
5.10.1.4.2 Mexico 83
5.10.1.5 Middle East 83
5.10.1.5.1 Africa 83
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
5.11 TECHNOLOGY ANALYSIS 86
5.11.1 KEY TECHNOLOGIES 86
5.11.1.1 RT-PCR 86
5.11.2 COMPLEMENTARY TECHNOLOGIES 86
5.11.2.1 INAAT (Isolated Nucleic Acid Amplification Technology) 86
5.11.3 ADJACENT TECHNOLOGIES 87
5.11.3.1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) 87
5.12 KEY CONFERENCES & EVENTS, 2025–2026 87
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 89
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 89
5.14.2 BUYING CRITERIA 90
5.15 INVESTMENT & FUNDING SCENARIO 91
5.16 CASE STUDY ANALYSIS 91
5.16.1 CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY 91
5.16.2 CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT 92
5.16.3 CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION 92
5.17 IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 93
5.17.1 INTRODUCTION 93
5.17.2 MARKET POTENTIAL OF AI 93
5.17.3 AI-USE CASES 94
5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 94
5.17.5 FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 95
5.18 TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 95
5.18.1 INTRODUCTION 95
5.18.2 KEY TARIFF RATES 95
5.18.3 PRICE IMPACT ANALYSIS 96
5.18.4 IMPACT ON COUNTRY/REGION 96
5.18.4.1 North America 96
5.18.4.2 Europe 97
5.18.4.3 Asia Pacific 97
5.18.5 IMPACT ON END-USE INDUSTRIES 97
5.18.5.1 Physicians’ Offices/Clinics 97
5.18.5.2 Hospitals 97
5.18.5.3 Research Institutes 98
6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE 99
6.1 INTRODUCTION 100
6.2 ASSAYS & KITS 100
6.2.1 RECURRENT PURCHASE TO PROPEL MARKET 100
6.3 INSTRUMENTS & ANALYZERS 104
6.3.1 INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES
TO DRIVE MARKET 104
6.4 SOFTWARE & SERVICES 107
6.4.1 UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE
TO SUPPORT MARKET GROWTH 107
7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 111
7.1 INTRODUCTION 112
7.2 RT-PCR 112
7.2.1 HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND 112
7.3 INAAT 116
7.3.1 COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET 116
7.4 OTHER TECHNOLOGIES 118
8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE 122
8.1 INTRODUCTION 123
8.2 BLOOD SAMPLES 123
8.2.1 ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES
TO PROPEL MARKET 123
8.3 URINE SAMPLES 126
8.3.1 NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND 126
8.4 OTHER SAMPLE TYPES 129
9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 133
9.1 INTRODUCTION 134
9.2 RESPIRATORY DISEASES 134
9.2.1 RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET 134
9.3 SEXUALLY TRANSMITTED DISEASES 138
9.3.1 RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET 138
9.4 HOSPITAL-ACQUIRED INFECTIONS 142
9.4.1 GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR
REDUCTION IN HAIS TO FUEL MARKET 142
9.5 CANCER 145
9.5.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS
TO DRIVE MARKET 145
9.6 HEPATITIS 148
9.6.1 INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP
POPULATIONS TO PROPEL MARKET 148
9.7 GASTROINTESTINAL DISORDERS 151
9.7.1 RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH 151
9.8 OTHER APPLICATIONS 154
10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 158
10.1 INTRODUCTION 159
10.2 HOSPITALS 159
10.2.1 CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET 159
10.2.1.1 Sepsis 163
10.2.1.1.1 Rising requirement for rapid diagnosis & treatment to fuel uptake 163
10.2.1.2 Gastroenteritis 163
10.2.1.2.1 Increasing admissions to critical care units and rising focus on molecular tools for diagnosis to fuel uptake 163
10.2.1.3 Meningoencephalitis 164
10.2.1.3.1 Initialization of targeted treatment due to high mortality risk to fuel market 164
10.2.1.4 Other diseases 164
10.3 PHYSICIANS’ OFFICES/CLINICS 165
10.3.1 RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET 165
10.4 RESEARCH INSTITUTES 167
10.4.1 INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND 167
10.5 OTHER END USERS 170
11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 173
11.1 INTRODUCTION 174
11.2 NORTH AMERICA 174
11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 177
11.2.2 US 180
11.2.2.1 High healthcare expenditure for advanced molecular diagnostic technologies to drive market 180
11.2.3 CANADA 183
11.2.3.1 Favorable government initiatives for early disease diagnosis awareness to fuel market 183
11.3 EUROPE 186
11.3.1 EUROPE: MACROECONOMIC OUTLOOK 187
11.3.2 GERMANY 189
11.3.2.1 Universal healthcare coverage and favorable growth for decentralized care settings to fuel market 189
11.3.3 UK 192
11.3.3.1 Rising prevalence of STIs to boost demand 192
11.3.4 FRANCE 196
11.3.4.1 High disease burden of infectious diseases and cancer to drive market 196
11.3.5 ITALY 198
11.3.5.1 Rising demand for high-precision diagnostic tools to support market growth 198
11.3.6 SPAIN 201
11.3.6.1 Rising incidence of respiratory illnesses and HIV to boost demand 201
11.3.7 REST OF EUROPE 203
11.4 ASIA PACIFIC 206
11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 208
11.4.2 CHINA 210
11.4.2.1 Increasing incidence of influenza and epidemics to propel market 210
11.4.3 JAPAN 214
11.4.3.1 Growing access to advanced & affordable healthcare services to fuel market 214
11.4.4 INDIA 217
11.4.4.1 Expanding healthcare access and increasing prevalence of HIV to propel market 217
11.4.5 REST OF ASIA PACIFIC 219
11.5 LATIN AMERICA 222
11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 223
11.5.2 BRAZIL 226
11.5.2.1 High incidence of hepatitis to support market uptake 226
11.5.3 MEXICO 228
11.5.3.1 Rising cases of TB and HAIs to fuel market 228
11.5.4 REST OF LATIN AMERICA 231
11.6 MIDDLE EAST & AFRICA 234
11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 235
11.6.2 KINGDOM OF SAUDI ARABIA (KSA) 238
11.6.2.1 Improvements in healthcare infrastructure to drive market 238
11.6.3 UNITED ARAB EMIRATES (UAE) 240
11.6.3.1 Rising technological advancements in molecular diagnostics to fuel market 240
11.6.4 REST OF MIDDLE EAST & AFRICA 243
12 COMPETITIVE LANDSCAPE 246
12.1 INTRODUCTION 246
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 246
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 246
12.3 REVENUE SHARE ANALYSIS, 2022−2024 248
12.4 MARKET SHARE ANALYSIS, 2024 249
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 251
12.5.1 STARS 251
12.5.2 EMERGING LEADERS 251
12.5.3 PERVASIVE PLAYERS 251
12.5.4 PARTICIPANTS 252
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 253
12.5.5.1 Company footprint 253
12.5.5.2 Region footprint 254
12.5.5.3 Product & service footprint 254
12.5.5.4 Technology footprint 255
12.5.5.5 Application footprint 255
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 256
12.6.1 PROGRESSIVE COMPANIES 256
12.6.2 RESPONSIVE COMPANIES 256
12.6.3 DYNAMIC COMPANIES 256
12.6.4 STARTING BLOCKS 256
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 258
12.6.5.1 Detailed list of key startups/SMEs 258
12.6.5.2 Competitive benchmarking of key emerging players/startups (1/2) 258
12.6.5.3 Competitive benchmarking of key startups/SMEs (2/2) 259
12.7 COMPANY VALUATION & FINANCIAL METRICS 259
12.7.1 FINANCIAL METRICS 259
12.7.2 COMPANY VALUATION 260
12.8 BRAND/PRODUCT COMPARISON 261
12.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 261
12.9 COMPETITIVE SCENARIO 262
12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 262
12.9.2 DEALS 263
12.9.3 EXPANSIONS 264
13 COMPANY PROFILES 265
13.1 KEY PLAYERS 265
13.1.1 DANAHER CORPORATION 265
13.1.1.1 Business overview 265
13.1.1.2 Products/Services offered 266
13.1.1.3 Recent developments 267
13.1.1.3.1 Product/Service launches & approvals 267
13.1.1.3.2 Deals 269
13.1.1.3.3 Expansions 269
13.1.1.4 MnM view 270
13.1.1.4.1 Key strengths 270
13.1.1.4.2 Strategic choices 270
13.1.1.4.3 Weaknesses & competitive threats 270
13.1.2 BIOMÉRIEUX 271
13.1.2.1 Business overview 271
13.1.2.2 Products/Services offered 272
13.1.2.3 Recent developments 273
13.1.2.3.1 Product/Service launches & approvals 273
13.1.2.3.2 Deals 273
13.1.2.4 MnM view 274
13.1.2.4.1 Key strengths 274
13.1.2.4.2 Strategic choices 274
13.1.2.4.3 Weaknesses & competitive threats 274
13.1.3 F. HOFFMANN-LA ROCHE LTD. 275
13.1.3.1 Business overview 275
13.1.3.2 Products/Services offered 276
13.1.3.3 Recent developments 277
13.1.3.3.1 Products/Services launches & approvals 277
13.1.3.3.2 Deals 278
13.1.3.3.3 Expansions 278
13.1.3.4 MnM view 279
13.1.3.4.1 Key strengths 279
13.1.3.4.2 Strategic choices 279
13.1.3.4.3 Weaknesses & competitive threats 279
13.1.4 ABBOTT 280
13.1.4.1 Business overview 280
13.1.4.2 Products/Services offered 281
13.1.4.3 Recent developments 282
13.1.4.3.1 Deals 282
13.1.4.4 MnM view 282
13.1.4.4.1 Key strengths 282
13.1.4.4.2 Strategic choices 283
13.1.4.4.3 Weaknesses & competitive threats 283
13.1.5 QIAGEN N.V. 284
13.1.5.1 Business overview 284
13.1.5.2 Products/Services offered 285
13.1.5.3 Recent developments 286
13.1.5.3.1 Product launches & approvals 286
13.1.5.3.2 Deals 287
13.1.5.3.3 Expansions 288
13.1.5.4 MnM view 288
13.1.5.4.1 Key strengths 288
13.1.5.4.2 Strategic choices 288
13.1.5.4.3 Weaknesses & competitive threats 288
13.1.6 QUIDELORTHO CORPORATION 289
13.1.6.1 Business overview 289
13.1.6.2 Products/Services offered 290
13.1.6.3 Recent developments 292
13.1.6.3.1 Product/Service launches & approvals 292
13.1.6.3.2 Deals 292
13.1.6.3.3 Expansions 293
13.1.7 CO-DIAGNOSTICS, INC. 294
13.1.7.1 Business overview 294
13.1.7.2 Products/Services offered 295
13.1.7.3 Recent developments 295
13.1.7.3.1 Deals 295
13.1.7.3.2 Expansions 296
13.1.8 BIOCARTIS 297
13.1.8.1 Business overview 297
13.1.8.2 Products/Services offered 299
13.1.8.3 Recent developments 299
13.1.8.3.1 Product/Service launches & approvals 299
13.1.8.3.2 Deals 300
13.1.9 SD BIOSENSOR, INC. 301
13.1.9.1 Business overview 301
13.1.9.2 Products/Services offered 302
13.1.9.3 Recent developments 303
13.1.9.3.1 Product/Service launches 303
13.1.9.3.2 Deals 303
13.1.9.3.3 Other developments 304
13.1.10 GENEDRIVE PLC 305
13.1.10.1 Business overview 305
13.1.10.2 Products/Services offered 306
13.2 OTHER PLAYERS 307
13.2.1 BINX HEALTH, INC. 307
13.2.2 MOLBIO DIAGNOSTICS LIMITED 308
13.2.3 OPGEN, INC. 310
13.2.4 GENOMADIX 310
13.2.5 VISBY MEDICAL, INC. 311
13.2.6 QUANTUMDX GROUP LTD. 311
13.2.7 DETECTACHEM 312
13.2.8 LABSYSTEMS DIAGNOSTICS OY 312
13.2.9 AKONNI BIOSYSTEMS, INC. 313
13.2.10 UBIQUITOME LIMITED 314
13.2.11 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD. 314
13.2.12 NUCLEIN, LLC 315
13.2.13 GENES2ME 316
13.2.14 AXXIN 317
13.2.15 HUWEL LIFESCIENCES 318
14 APPENDIX 319
14.1 DISCUSSION GUIDE 319
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 324
14.3 CUSTOMIZATION OPTIONS 326
14.4 RELATED REPORTS 326
14.5 AUTHOR DETAILS 327
LIST OF TABLES
TABLE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 34
TABLE 2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
KEY DATA FROM PRIMARY SOURCES 41
TABLE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 50
TABLE 4 REGIONAL HIV DATA, 2024 62
TABLE 5 AVERAGE SELLING PRICING TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023–2025 67
TABLE 6 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR
DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023–2025 68
TABLE 7 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR
DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025 68
TABLE 8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS 71
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 75
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 75
TABLE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 76
TABLE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
PORTER’S FIVE FORCES ANALYSIS 78
TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE 80
TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 82
TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 20 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST
OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 88
TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS (%) 90
TABLE 22 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 90
TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 94
TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 95
TABLE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT &
SERVICE, 2023–2030 (USD MILLION) 100
TABLE 26 KEY ASSAYS & KITS CURRENTLY AVAILABLE 101
TABLE 27 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS,
BY REGION, 2023–2030 (USD MILLION) 102
TABLE 28 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 29 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS &
KITS, BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 30 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 31 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 32 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 33 KEY INSTRUMENTS & ANALYZERS CURRENTLY AVAILABLE 104
TABLE 34 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 35 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 36 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 38 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 39 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE 108
TABLE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 42 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 43 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 44 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 45 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 46 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 47 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 112
TABLE 48 KEY RT-PCR-BASED PRODUCTS CURRENTLY AVAILABLE 113
TABLE 49 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 50 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 51 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 53 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 54 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 55 KEY INAAT-BASED PRODUCTS CURRENTLY AVAILABLE 116
TABLE 56 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 57 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 58 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 59 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 60 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 61 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 62 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 63 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 64 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 65 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 66 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 67 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 68 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 123
TABLE 69 KEY BLOOD SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE 124
TABLE 70 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES,
BY REGION, 2023–2030 (USD MILLION) 124
TABLE 71 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 72 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 73 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 74 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 75 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 76 KEY URINE SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE 127
TABLE 77 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES,
BY REGION, 2023–2030 (USD MILLION) 127
TABLE 78 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 79 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 80 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 81 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 82 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 83 KEY OTHER SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE 130
TABLE 84 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 85 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 86 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER
SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 87 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 88 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 89 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 90 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 134
TABLE 91 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR RESPIRATORY
DISEASES CURRENTLY AVAILABLE 135
TABLE 92 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY
DISEASES, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 93 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 94 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 95 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 96 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 97 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 98 NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES,
2023–2030 (IN MILLIONS) 138
TABLE 99 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR SEXUALLY TRANSMITTED DISEASES CURRENTLY AVAILABLE 139
TABLE 100 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 101 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 102 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 103 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 104 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 105 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 106 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 107 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 108 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 109 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 110 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 111 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 112 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 113 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 114 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 115 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 116 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 117 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 118 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR HEPATITIS
CURRENTLY AVAILABLE 149
TABLE 119 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION) 149
TABLE 120 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 121 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 122 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 123 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 124 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 125 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR GASTROINTESTINAL DISORDERS CURRENTLY AVAILABLE 152
TABLE 126 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 152
TABLE 127 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 128 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 129 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 130 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 131 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 132 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR OTHER APPLICATIONS CURRENTLY AVAILABLE 155
TABLE 133 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 134 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 135 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 136 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 137 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 138 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 139 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 159
TABLE 140 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 160
TABLE 141 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 161
TABLE 142 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 143 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 144 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 145 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 146 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 147 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 148 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 149 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 150 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 151 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 152 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 153 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 154 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 155 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 156 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 157 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 158 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 159 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS,
BY REGION, 2023–2030 (USD MILLION) 171
TABLE 160 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 161 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 162 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 163 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 164 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 165 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2023–2030 (USD MILLION) 174
TABLE 166 NORTH AMERICA: MACROECONOMIC INDICATORS 176
TABLE 167 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 168 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 177
TABLE 169 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 178
TABLE 170 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 178
TABLE 171 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 179
TABLE 172 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 179
TABLE 173 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 181
TABLE 174 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 181
TABLE 175 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 182
TABLE 176 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 182
TABLE 177 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 183
TABLE 178 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 184
TABLE 179 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 184
TABLE 180 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 185
TABLE 181 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185
TABLE 182 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 186
TABLE 183 EUROPE: MACROECONOMIC INDICATORS 187
TABLE 184 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 185 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 188
TABLE 186 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 188
TABLE 187 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 188
TABLE 188 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 189
TABLE 189 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 189
TABLE 190 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 191
TABLE 191 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 191
TABLE 192 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 191
TABLE 193 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 192
TABLE 194 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 192
TABLE 195 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 194
TABLE 196 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 194
TABLE 197 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 194
TABLE 198 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 195
TABLE 199 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 195
TABLE 200 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 196
TABLE 201 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 197
TABLE 202 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 197
TABLE 203 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198
TABLE 204 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 198
TABLE 205 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 199
TABLE 206 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 199
TABLE 207 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 200
TABLE 208 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200
TABLE 209 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 210 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 202
TABLE 211 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202
TABLE 212 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 202
TABLE 213 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203
TABLE 214 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 215 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 204
TABLE 216 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 204
TABLE 217 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 205
TABLE 218 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 205
TABLE 219 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 206
TABLE 220 ASIA PACIFIC: MACROECONOMIC INDICATORS 207
TABLE 221 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 222 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 208
TABLE 223 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 209
TABLE 224 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 209
TABLE 225 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 210
TABLE 226 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 210
TABLE 227 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 211
TABLE 228 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 212
TABLE 229 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 212
TABLE 230 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213
TABLE 231 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 232 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 215
TABLE 233 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 215
TABLE 234 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 215
TABLE 235 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216
TABLE 236 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 216
TABLE 237 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 218
TABLE 238 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 218
TABLE 239 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 218
TABLE 240 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 219
TABLE 241 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 219
TABLE 242 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 220
TABLE 243 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 221
TABLE 244 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 221
TABLE 245 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 222
TABLE 246 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 222
TABLE 247 LATIN AMERICA: MACROECONOMIC INDICATORS 223
TABLE 248 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 224
TABLE 249 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 224
TABLE 250 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 224
TABLE 251 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 225
TABLE 252 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 225
TABLE 253 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 226
TABLE 254 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 227
TABLE 255 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227
TABLE 256 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 227
TABLE 257 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 228
TABLE 258 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 228
TABLE 259 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 229
TABLE 260 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 229
TABLE 261 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 230
TABLE 262 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230
TABLE 263 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 231
TABLE 264 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 232
TABLE 265 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 232
TABLE 266 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 233
TABLE 267 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 233
TABLE 268 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 234
TABLE 269 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 235
TABLE 270 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 236
TABLE 271 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 236
TABLE 272 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 236
TABLE 273 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 237
TABLE 274 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 237
TABLE 275 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 238
TABLE 276 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 239
TABLE 277 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 239
TABLE 278 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 239
TABLE 279 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240
TABLE 280 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 240
TABLE 281 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 241
TABLE 282 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 241
TABLE 283 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 242
TABLE 284 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 242
TABLE 285 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET,
BY END USER, 2023–2030 (USD MILLION) 243
TABLE 286 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 244
TABLE 287 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 244
TABLE 288 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 244
TABLE 289 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 245
TABLE 290 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 245
TABLE 291 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, JANUARY 2021−JULY 2025 246
TABLE 292 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 250
TABLE 293 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT 254
TABLE 294 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 254
TABLE 295 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 255
TABLE 296 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT 255
TABLE 297 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 258
TABLE 298 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS (1/2) 258
TABLE 299 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 259
TABLE 300 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 262
TABLE 301 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEALS,
JANUARY 2021–JULY 2025 263
TABLE 302 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–JULY 2025 264
TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW 265
TABLE 304 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 266
TABLE 305 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 267
TABLE 306 DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025 269
TABLE 307 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025 269
TABLE 308 BIOMÉRIEUX: COMPANY OVERVIEW 271
TABLE 309 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 272
TABLE 310 BIOMÉRIEUX: PRODUCT/SERVICE APPROVALS, JANUARY 2021–JULY 2025 273
TABLE 311 BIOMÉRIEUX: DEALS, JANUARY 2021–JULY 2025 273
TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 275
TABLE 313 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 276
TABLE 314 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES LAUNCHES &
APPROVALS, JANUARY 2021–JULY 2025 277
TABLE 315 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2025 278
TABLE 316 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JULY 2025 278
TABLE 317 ABBOTT: COMPANY OVERVIEW 280
TABLE 318 ABBOTT PRODUCTS/SERVICES OFFERED 281
TABLE 319 ABBOTT: DEALS, JANUARY 2021–JULY 2025 282
TABLE 320 QIAGEN N.V.: COMPANY OVERVIEW 284
TABLE 321 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 285
TABLE 322 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 286
TABLE 323 QIAGEN N.V.: DEALS, JANUARY 2021–JULY 2025 287
TABLE 324 QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025 288
TABLE 325 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 289
TABLE 326 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED 290
TABLE 327 QUIDELORTHO CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 292
TABLE 328 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–JULY 2025 292
TABLE 329 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025 293
TABLE 330 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW 294
TABLE 331 CO-DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED 295
TABLE 332 CO-DIAGNOSTICS, INC.: DEALS, JANUARY 2021–JULY 2025 295
TABLE 333 CO-DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2021–JULY 2025 296
TABLE 334 BIOCARTIS: COMPANY OVERVIEW 297
TABLE 335 BIOCARTIS: PRODUCTS/SERVICES OFFERED 299
TABLE 336 BIOCARTIS: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–JULY 2025 299
TABLE 337 BIOCARTIS: DEALS, JANUARY 2021–JULY 2025 300
TABLE 338 SD BIOSENSOR, INC.: BUSINESS OVERVIEW 301
TABLE 339 SD BIOSENSOR, INC.: PRODUCTS/SERVICES OFFERED 302
TABLE 340 SD BIOSENSOR, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JULY 2025 303
TABLE 341 SD BIOSENSOR, INC.: DEALS, JANUARY 2021–JULY 2025 303
TABLE 342 SD BIOSENSOR, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2025 304
TABLE 343 GENEDRIVE PLC: COMPANY OVERVIEW 305
TABLE 344 GENEDRIVE PLC: PRODUCTS/SERVICES OFFERED 306
TABLE 345 BINX HEALTH, INC.: COMPANY OVERVIEW 307
TABLE 346 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 308
TABLE 347 OPGEN, INC.: COMPANY OVERVIEW 310
TABLE 348 GENOMADIX: COMPANY OVERVIEW 310
TABLE 349 VISBY MEDICAL, INC.: COMPANY OVERVIEW 311
TABLE 350 QUANTUMDX GROUP LTD.: COMPANY OVERVIEW 311
TABLE 351 DETECTACHEM: COMPANY OVERVIEW 312
TABLE 352 LABSYSTEMS DIAGNOSTICS OY: COMPANY OVERVIEW 312
TABLE 353 AKONNI BIOSYSTEMS, INC.: COMPANY OVERVIEW 313
TABLE 354 UBIQUITOME LIMITED: COMPANY OVERVIEW 314
TABLE 355 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW 314
TABLE 356 NUCLEIN, LLC: COMPANY OVERVIEW 315
TABLE 357 GENES2ME: COMPANY OVERVIEW 316
TABLE 358 AXXIN: COMPANY OVERVIEW 317
TABLE 359 HUWEL LIFESCIENCES: COMPANY OVERVIEW 318
LIST OF FIGURES
FIGURE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
SEGMENTATION & REGIONAL SCOPE 33
FIGURE 2 YEARS CONSIDERED 35
FIGURE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 37
FIGURE 4 PRIMARY SOURCES 40
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 42
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 43
FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 44
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
FIGURE 9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 48
FIGURE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 49
FIGURE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 51
FIGURE 13 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 52
FIGURE 14 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE,
2025 VS. 2030 (USD MILLION) 52
FIGURE 15 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 53
FIGURE 16 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 54
FIGURE 17 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION,
2025 VS. 2030 (USD MILLION) 55
FIGURE 18 INCREASING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS
TECHNOLOGIES TO PROPEL MARKET 56
FIGURE 19 ASSAYS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57
FIGURE 20 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57
FIGURE 21 OTHER SAMPLE TYPES SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 58
FIGURE 22 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET
DURING FORECAST PERIOD 58
FIGURE 23 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 59
FIGURE 24 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 59
FIGURE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 26 PATENT ANALYSIS FOR POINT OF CARE MOLECULAR DIAGNOSTICS
(JANUARY 2014–DECEMBER 2024) 70
FIGURE 27 VALUE CHAIN ANALYSIS OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 72
FIGURE 28 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 74
FIGURE 29 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 76
FIGURE 30 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 31 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 89
FIGURE 33 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 90
FIGURE 34 NUMBER OF DEALS & FUNDING ACTIVITIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 91
FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 93
FIGURE 36 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 176
FIGURE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 207
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, 2022–2024 248
FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET (2024) 249
FIGURE 40 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 252
FIGURE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT 253
FIGURE 42 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 257
FIGURE 43 EV/EBITDA OF KEY VENDORS 259
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 260
FIGURE 45 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS 261
FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 266
FIGURE 47 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 272
FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 276
FIGURE 49 ABBOTT: COMPANY SNAPSHOT (2024) 281
FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 285
FIGURE 51 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 290
FIGURE 52 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2024) 294
FIGURE 53 BIOCARTIS: COMPANY SNAPSHOT (2022) 298
FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT (2024) 301
FIGURE 55 GENEDRIVE PLC: COMPANY SNAPSHOT (2024) 305
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11